2023-09-12 06:14:55 ET
Related stories
- Compare metrics for HUMA to ORCL, SGHT, SLRN, WRK
- WestRock: Solid Asset-Based, But (Likely) Not The Right Time
- Reevaluating Acelyrin: The Impact Of Mixed Izokibep Results (Rating Downgrade)
- Oracle Corporation ( ORCL ) Q1 2024 Earnings Call Transcript
- Oracle: The Problem With All The Hype Around AI
- Oracle: Optimistic Valuation, Yet The Company Has To Deliver
- Oracle Is Not An AI Wannabe, But Is ORCL Stock A Buy?
- Oracle declares $0.40 dividend
- Oracle Non-GAAP EPS of $1.19 beats by $0.04, revenue of $12.45B misses by $20M
- Oracle may top estimates led by cloud, but quality an issue: Citi
- Humacyte: Major Catalysts Ahead, Solid Prospects, Low Prices
For further details see:
Biggest stock movers today: WestRock, Oracle and more